Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
1 2 3 4 5 … 61 Next »

Psoriasis biomarkers to predict efficacy of bio treatments

Threaded Mode
Psoriasis biomarkers to predict efficacy of bio treatments
Fred Offline
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 71,368
Threads: 4,140
Joined: Aug 2011
Gender: Male
Location: France
Psoriasis Score: Zero
Psoriatic Arthritis Score: 1
PQOLS: 1
Treatment: Bimzelx / Coconut Oil
#1
9 hours ago
This study focused on the potential of MX1, OAS1, and RSAD2 genes as biomarkers for predicting the efficacy of biological therapies for psoriasis.

Quote:
This study aims to explore the genes that have predictive value for the effect of biologic therapy and provide a basis for personalized therapy in psoriasis. We analyzed gene expression data from seven publicly available datasets from the Gene Expression Omnibus (GEO) database.

Differentially expressed immune-related genes (DEIRGs) were identified using the limma package, followed by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. MX1, OAS1, and RSAD2 were identified using GSE2737 and GSE78097. Cross-dataset validation of MX1, OAS1, and RSAD2 expression dynamics was performed using pre- and post-treatment specimens from GSE69967, GSE51440, and GSE11903. The expression levels of MX1, OAS1, and RSAD2 in clinical samples before and after treatment were further evaluated using an immunohistochemical (IHC) assay.

The expression levels of MX1 and OAS1 in psoriatic lesional skin were positively correlated with PASI scores, and their expression in post-treatment lesions was significantly reduced compared to pretreatment lesions. RSAD2 expression in psoriatic lesional skin demonstrated no significant correlation with PASI scores, and its expression levels remained statistically unchanged between pretreatment and post-treatment psoriatic skin lesions.

Baseline expression of MX1 and OAS1 differed significantly between responders and nonresponders, whereas RSAD2 showed no significant intergroup difference. Owing to the small and imbalanced sample (17 responders vs 3 nonresponders) with complete group separation for MX1/OAS1, these results require cautious interpretation. MX1 and OAS1 may serve as candidate biomarkers for monitoring biologic efficacy in psoriasis and warrant further validation in larger studies.

Source: onlinelibrary.wiley.com

*Funding: Hubei Polytechnic University | Natural Science Foundation of Hubei Province.
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
  Bio treatments for psoriasis & cancer risk Fred 2 578 Sat-07-11-2026, 13:14 PM
Last Post: Fred
  Bimzelx efficacy and safety in Chinese patients Fred 0 1,569 Mon-25-05-2026, 12:43 PM
Last Post: Fred
  Efficacy and safety of Imsidolimab for pustular psoriasis Fred 0 1,334 Wed-29-04-2026, 14:58 PM
Last Post: Fred
  Erythrodermic psoriasis and systemic treatments Fred 0 2,232 Sat-18-04-2026, 12:28 PM
Last Post: Fred
  Biologic efficacy in patients with psoriasis (study) Fred 0 1,288 Sat-18-04-2026, 11:42 AM
Last Post: Fred



Users browsing this thread: 1 Guest(s)
    About | Contact us | Login | Register | Home | Cookies/GDPR | RSS Syndication | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2026 Psoriasis Club | All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB | Social